Background: Clomifene citrate (CC) is accepted as the first-line method for ovulation induction
INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most prevalent female endocrinopathy affecting at least 7% of all women in the fertile age group (Kousta et al., 1997) .The symptoms of PCOS include irregular or absent ovulation, hyperandrogenism manifesting as hirsutism and persistent acne, and characteristic changes in ovarian morphology. The syndrome is often accompanied by abdominal obesity and insulin resistance and, as such, is frequently associated with the metabolic syndrome. PCOS is diagnosed in 75% of women with anovulatory infertility (Kousta et al., 1997) : successful treatment by ovulation induction (OI) will result in the delivery of a single healthy baby avoiding the complications of multiple pregnancy and ovarian hyperstimulation syndrome (OHSS).
For almost 50 years, the undisputed first-line medication for OI in PCOS has been clomifene citrate (CC). CC is a simple, cheap and effective method to induce ovulation with minimal sideeffects. Acting as an estrogen receptor antagonist in the hypothalamus and anterior pituitary, thus increasing the secretion of FSH, CC induces ovulation in 75-80% of patients but pregnancy is achieved in only 35-40% (Homburg, 2005) . The discrepancy between ovulation and pregnancy rates is thought to be related mainly to the anti-estrogenic effect of CC on cervical function and on endometrial receptivity. Increased LH secretion induced by CC, which does not occur with FSH administration, may also reduce the likelihood of conception (Hamilton-Fairley and Franks, 1990) .
When CC resistance (failure to ovulate with maximal doses) or CC failure (failure to conceive despite ovulation in six or more cycles of treatment) occurs, the accepted second-line of treatment is direct ovarian stimulation and OI with injectable FSH. In the earlier days of gonadotropin administration, this was fraught with the complications of multiple pregnancy and OHSS which could even be life-threatening (Hamilton-Fairley and Franks, 1990) owing to the high sensitivity of polycystic ovaries to FSH. Fortunately, these complications have been largely overcome following the introduction of low-dose protocols for the administration of FSH, which achieve mono-ovulation in 70% of cycles (Polson et al., 1987; Homburg and Howles, 1999) .
This has almost completely eliminated the prevalence of severe OHSS and has lowered the incidence of multiple pregnancy from 34 to <6% (Hamilton-Fairley and Franks, 1990; Homburg and Howles, 1999) .
These clear benefits of the low-dose FSH protocol as a second-line therapy suggested the possibility of using it as a first-line approach for OI in PCOS, which might result in an increased singleton pregnancy rate and shorter treatment to pregnancy interval. The aim of this RCT was to test the hypothesis that the (cumulative) pregnancy rate (PR) and live birth rates (LBR) in OI are higher with low-dose FSH than with CC as a first-line treatment.
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MATERIALS AND METHODS
A prospective, randomized, multicentre, multinational, controlled trial in 10 centres throughout Europe and South America. This study was reported according to the CONSORT criteria for RCTs comparing medical treatment in two different arms.
Subjects were <40 years old. There were no weight or BMI restrictions. Tubo-peritoneal evaluation was performed only in subjects with a previous history of pregnancy resulting in a A power calculation, using Russ Lenth's power and sample size comparing two proportions (Lenth, 2006 (Lenth, -2009 demonstrated that 150 subjects were required in each arm to achieve a relative increase in PR of 50% from 35 to 52.5% with 80% power, a significance level of 0.05 and allowing for a total of 50 drop outs from the study. was given s.c. in a low-dose protocol starting with 50 IU on cycle day 4, with weekly increments of 25 IU as necessary to induce a follicular response (Leader, 2006) . Treatment cycles were monitored by ultrasound examination of follicle number and size and endometrial thickness starting on Day 11 of the cycle for both CC and FSH cycles. Repeat examination was performed every 1-3 days as clinically indicated until the criterion for hCG administration (10 000 IU i.m.) was reached (at least one follicle ≥17 mm diameter). hCG was withheld if three or more follicles of .15 mm diameter were seen on ultrasound. Intercourse was advised on the day of hCG and the following day. Clinical pregnancy was defined as a Clomifene or FSH for first-line treatment of anovulation 117 6 pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs with at least one foetus at 6-7 weeks gestation and this pregnancy was deemed as ongoing pregnancy if it continued for more than 20 completed weeks of gestation. A miscarriage was defined as the spontaneous loss of a clinical pregnancy before 20 completed weeks of gestation and a multiple pregnancy as one in which there was more than one foetus. A live birth was defined as the birth of a viable infant, reported on a clinical research form transmitted to the coordinating centre.
Each participating centre received appropriate ethical and other regulatory committee approvals (registered trial ISRCTN41865643). An informed consent form was signed by every participant in the study.
All biochemical analyses were performed with commercially available kits. LH and FSH were measured using a two-step immunoassay, total testosterone with a standard immunoassay, androstendione and sex hormone-binding globulin with an enzyme immunoassay, dehydroepiandrosterone sulphate (DHEAS) and 17-hydroxy progesterone with a delayed onestep immunoassay, fasting glucose with hexokinase/glucose-6-phosphate dehydrogenase methodology and insulin by immunoradiometric assay.
Statistical analyses
Descriptive statistical analyses were performed using χ 2 and t-tests. Both per protocol analysis and intention-to-treat analysis were carried out. To calculate cumulative PR and LBR, we used the Kaplan-Meier survival analysis. An important advantage of the Kaplan-Meier curve is that the method can take into account 'censored' data, which are losses caused by drop outs from the study before the final outcome (pregnancy) is observed (Daya, 2005) . The log-rank test was used to test the probability that there was a difference in survival scores between the CC and FSH groups. Statistical analysis was performed using the Statistical Package for the Social Sciences 15.0 software for Windows (SPSS Inc., Chicago, IL, USA). Statistical significance was set at P<0.05.
RESULTS
Of 302 subjects randomized, 143 received CC (340 cycles) and 159 received low-dose FSH (326 cycles). The only demographic or clinical differences between the randomized groups, confirmed by multivariate analysis, were a higher prevalence of clinical hyperandrogenism (P<0.01) and higher serum DHEAS concentrations (P<0.04) in the CC group ( (Figure 1) . Thus, only one subject withdrew from the study owing to a treatment-related effect (overstimulation). For analysis, all started treatment cycles were considered. 
Intention-to-treat analysis
The intention-to-treat analysis revealed that the PR per cycle was higher after OI with FSH 
Per protocol analysis
Of the women receiving CC, 63% ovulated on the minimum dose of 50 mg a day resulting in 39 of the 54 pregnancies (72.2%) achieved with CC. Eight women (6.5%) were CC resistant, failing to ovulate on 150 mg/day. Treatment was cancelled in 19 (6.6%) of the 288 cycles of low- Table 2) .
Clinical pregnancies in the CC group were achieved fairly evenly over the three cycles (33, 41
and 26% of the pregnancies, respectively), whereas those from FSH were mainly achieved in cycle 1 (52.6%) with a further 35.5% in cycle 2. The PR after the first cycle of treatment was twice as high after OI with FSH (30%) than after OI with CC (14.6%, 95% CI 5.3-25.8, P=0.003).
The PR after the first two cycles of treatment was also higher after OI with FSH (50.7%) than after OI with CC (32.5%, P=0.003).
By survival analysis, using the Kaplan-Meier and log-rank test, the cumulative clinical PR after three cycles was 41.2% for the CC group compared with 52.1% for the FSH group (P=0.021).
The cumulative LBR after three cycles was 36.9% for the CC group compared with 47.4% for the FSH group (P=0.031; Figure 2 ).
Cost of visits
The monetary costs of follicle tracking and administrative were the same for both treatments (data not shown). The number of ultrasound monitoring visits per cycle was 3.3 for CC and 4.1 for FSH, the number of visits per live birth therefore was 12.3% greater with CC than FSH.
Overall, on per protocol analysis, there was both a relative and an absolute advantage in reproductive outcome after OI with low-dose FSH when compared with OI with CC with respect to clinical PR after the first cycle (100 and 13%, respectively), PR per cycle over the three cycles (77 and 13%), cumulative PR within three cycles (27 and 11%) and cumulative LBR within three cycles (27 and 10%).
DISCUSSION
Our study demonstrated that in treatment-naive patients with PCOS, the reproductive outcome after OI with low-dose FSH was significantly better than after OI with CC, with respect to clinical Clomifene or FSH for first-line treatment of anovulation 121 6 PR and LBR per (first) cycle, cumulative clinical PR and LBR over three cycles and time to pregnancy. These results are in line with the trend observed in another similar study but which did not reach significance because of the small numbers involved (n=38 in each group) (Lopez et al., 2004) .
Although from the patient perspective CC is more convenient (oral intake) and cheaper than low-dose FSH, this relative advantage for CC is reduced as current guidelines in most countries now recommend the same intensity of monitoring with ultrasound for CC cycles as for low-dose FSH treatment. Furthermore, 7-15% of subjects do not ovulate with maximal doses of CC and 15-50% of those who ovulate demonstrate a suppressed thin endometrium which considerably reduces the chance of pregnancy (Gonen and Casper, 1990; Homburg, 2005) . In contrast, OI with low-dose FSH is not associated with an anti-endometrial effect and only rarely associated with ovulation failure (Homburg and Howles, 1999) .
While our study confirmed our hypothesis that OI with low-dose FSH results in a high PR and LBR, the reproductive outcome after OI with CC was better than expected (high PR and LBR) and urprisingly was associated with a complete absence of multiple pregnancies (Homburg, 2005) . We hypothesize that these positive outcomes after OI with CC can be explained by the low starting dose (50 mg/day), the consistent use of ultrasound monitoring, patient management in specialized OI settings and accurate timing of sexual intercourse. The criteria for the timing of hCG administration in both arms were the same. Although it has been common practice to administer hCG in CC cycles at a later stage of follicular growth than in FSH cycles, there is little evidence to support this practice which has also been recently disputed (Farhi et al., 2010) . Further, the high PRs following CC in this study suggest that using the same criteria for hCG administration for both arms did not influence results.
Although differences in cost and convenience may limit the choice of FSH as first-line treatment in some settings, our results may justify OI with low-dose FSH as a first line of treatment in other settings where this is financially possible and where there is access to the required level of monitoring expertise. While we agree that the cost of recombinant human FSH is much higher than CC, this cost difference is offset by a number of factors: (i) The likelihood of pregnancy after the first cycle of OI with low-dose FSH is twice as high than after OI with CC; (ii) Follicle tracking and administrative costs are the same for both treatments-the number of visits per live birth therefore is greater with CC than FSH and (iii) The psychological burden on women taking CC who undergo 6-12 cycles without conceiving before progressing to low-dose FSH therapy should also be considered.
In conclusion, our study has, for the first time, shown that reproductive outcome is superior after OI with low-dose FSH when compared with OI with CC. These data may be utilized when balancing the pros and cons of initiating OI with low-dose FSH rather than OI with CC for women with PCOS-associated anovulatory infertility.
